about
Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) miceHigh log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapyClinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture processJanus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrosInhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy.Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastisiRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of thConditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transferAllogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMTAssociation of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantationAdult metachromatic leukodystrophy treated by allo-SCT and a review of the literature.Immunotherapeutic approaches to treat multiple myelomaA phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party oCentre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas.B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs.CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood anCombination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs.Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivoLB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application.Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic AnemiaImproving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice.Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors.Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT).Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation.
P50
Q27318729-BC5E7043-0765-4B7B-87CE-20E6FC01CD1EQ27334458-D42EC878-35E4-4A7C-9311-BFBB9F5D4C5BQ28743568-FB9E4A0C-0E87-4C13-94BC-61D2C11B961EQ33442629-FCD3C732-68BC-4573-A6EC-675C07502146Q34272525-3FD9B986-C8F9-48DB-8883-D4B1D88B195EQ34580132-A8D7567D-9AD2-4A51-A219-E092DDAECADBQ35146316-D7C410DF-F7FD-49FE-9688-A703B2830E29Q35546869-5DDDE5A4-E492-4716-9EE5-E3630959F940Q35586590-1AC3A2AD-B7C1-4E0A-9A70-5C25F6B7E402Q35647641-B3502AD7-D63E-4943-A4B8-AD0386D2E633Q35799180-D828510A-3769-44FC-B355-A3E825F55ABAQ36000415-5B6E65F6-69D2-4416-9647-93D95064E5DDQ36036334-31E3CD47-B480-42F0-832C-0E2228FA9AF3Q36556944-448D1414-9CB7-4BA7-A211-0AE77D414270Q37806061-2A134765-F551-464D-B30C-246A8C44E768Q38171067-DFB5ADA8-F65B-46C8-9038-C4F749A68CCFQ38674730-F14C0D15-B75C-4789-A801-D4189F048EF3Q38685562-188F89CC-67FC-466A-9E6F-33CFAACA11A6Q38739050-46519783-E760-468F-A77E-5751BA1EBB7AQ38893877-B9596B84-7FD2-45B5-9731-BD4E0F1B821FQ38951104-7448703F-8919-44B6-AC39-FDC7EA1C403AQ39341475-FC8AB612-9223-42D9-B942-4E123E2EDB2EQ39412098-82753F69-0AC5-4CB5-912B-8E0DD924CEC6Q39448429-967B7E99-D6E7-4F6E-9907-C41FE8ED2D58Q40261602-128FC336-B3A6-4012-AB90-F35118462E19Q40831363-378E2F2E-606E-49BE-9322-49033D6AC337Q40991233-BB510796-0C15-467A-872D-EB5EFEA34557Q41179473-E3C960EA-8D62-4E04-BC70-674E9B4C7714Q41179482-EC8B0E33-476B-4CFA-A907-BC2A9075BCF7Q41997533-38FF75C7-40A4-4697-8E53-351B1E490248Q43234209-7C8A8ABC-4DBE-4796-98D7-B335D0C70681Q44409145-A4A89CF7-F9D3-4CEA-8275-A5A755C1914DQ45214962-B361BDC8-AF82-4232-9131-E891D4293486Q45273993-587846CE-26FA-4DF4-8255-1BB20E2CD7F0Q45767689-BA0B1B3B-1F04-4F4A-B3C0-5F338B802C53Q47570536-A796AC8C-3D9A-4BB7-95C1-583BBD69446CQ47595821-9512FBCC-29B8-4619-BE7F-AF0F30496D7CQ47817994-47D04629-0392-46AA-96DF-F1FD61AAB332Q48255469-641DD9DC-3D9B-4C59-870E-66FBC3E1278DQ49346538-C3D09EDD-682B-49CA-8724-0664D0026275
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicolaas Schaap
@ast
Nicolaas Schaap
@en
Nicolaas Schaap
@es
Nicolaas Schaap
@nl
type
label
Nicolaas Schaap
@ast
Nicolaas Schaap
@en
Nicolaas Schaap
@es
Nicolaas Schaap
@nl
prefLabel
Nicolaas Schaap
@ast
Nicolaas Schaap
@en
Nicolaas Schaap
@es
Nicolaas Schaap
@nl
P106
P31
P496
0000-0001-7696-4752